Earnings Call Summary | Teladoc Health(TDOC.US) Q1 2024 Earnings Conference
Earnings Call Summary | Teladoc Health(TDOC.US) Q1 2024 Earnings Conference
The following is a summary of the Teladoc Health, Inc. (TDOC) Q1 2024 Earnings Call Transcript:
以下是Teladoc Health, Inc.(TDOC)2024年第一季度業績電話會議記錄摘要:
Financial Performance:
財務業績:
Teladoc reported Q1 revenue of $646 million, an increase of 3% year-over-year, surpassing their forecast.
The Integrated Care segment reported an 8% YoY growth, with revenue of $377 million and a margin expansion to 12.6%.
The BetterHelp segment saw a decline of 3.7%, reporting a revenue of $269 million.
Adjusted EBITDA margin improved by 140 basis points YoY to 9.8%, with an adjusted EBITDA of $63 million growing nearly 20% year-over-year.
Teladoc held over $1 billion in cash and cash equivalents at the end of the quarter.
Teladoc報告稱,第一季度收入爲6.46億美元,同比增長3%,超過了他們的預期。
綜合醫療板塊報告同比增長8%,收入爲3.77億美元,利潤率增長至12.6%。
BetterHelp板塊下降了3.7%,報告收入爲2.69億美元。
調整後的息稅折舊攤銷前利潤率同比增長140個點子至9.8%,調整後的息稅折舊攤銷前利潤爲6,300萬美元,同比增長近20%。
截至本季度末,Teladoc持有超過10億美元的現金和現金等價物。
Business Progress:
業務進展:
Chronic Care enrolment increased 9% YoY in Q1.
The US Integrated Care members grew by 8% over the prior year to $91.8 million, and the company expects to increase this number by the year-end further.
The company increased its US Integrated Care membership outlook for the full year, following the addition of two million members in Q1.
It expanded its services with a major health benefits provider, adding a diabetes program to the provider's offering.
Teladoc is focusing on its international expansion, especially in English-speaking countries.
The company remains committed to a Direct-to-Consumer (DTC) strategy for BetterHelp, aiming to reinforce its position in the DTC marketplace.
第一季度慢性病入學人數同比增長9%。
美國綜合醫療的成員比上年增長了8%,達到9180萬美元,該公司預計到年底這一數字將進一步增加。
繼第一季度增加200萬會員之後,該公司提高了全年美國綜合醫療會員的前景。
它通過一家主要的健康福利提供者擴大了服務範圍,在提供者的產品中增加了糖尿病計劃。
Teladoc專注於其國際擴張,尤其是在英語國家。
該公司仍然致力於爲BetterHelp實施直接面向消費者(DTC)的戰略,旨在鞏固其在DTC市場的地位。
More details: Teladoc Health IR
更多詳情: Teladoc 健康 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。
譯文內容由第三人軟體翻譯。